CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Rao, A.; Ryan, C. J.; VanderWeele, D. J.; Heller, G.; Lewis, L. D.; Watt, C.; Chen, R. C.; Grubb, R.; Hahn, O. M.; Beltran, H.; Morris, M. J. |
| Abstract Title: | CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500012 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.TPS181 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS181 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
